SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology 2004; 39: 85761.
  • 2
    de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement. J Hepatol 2003; 39 (Suppl. 1): P3P25.
  • 3
    Liaw YF, Leung N, Guan R, Lau GK, Merican I, Asian-Pacific Consensus Working Parties on Hepatitis B. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol 2003; 18: 23945.
  • 4
    Yang LM, Xu KC, Zhao YL, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis 2002; 3: 1503.
  • 5
    Iloeje UH, Yang HI, Su J, et al. Viral load is a strong predictor of hepatocellular carcinoma risk in people chronically infected with hepatitis B virus and with normal serum alanine aminotransferases (abstract). J Hepatol 2005; 42 (Suppl. 2): 179.
  • 6
    Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 7448.
  • 7
    Fattovich G, Rugge M, Brollo L, et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 16772.
  • 8
    van Nunen AB, Hansen BE, Suh DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferases. Gut 2003; 52: 4204.
  • 9
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 8036.
  • 10
    Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 13945.
  • 11
    Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186: 295301.
  • 12
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 31223.
  • 13
    Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295301.
  • 14
    Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46: 5628.
  • 15
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 8007.
  • 16
    Chang TT, Gish R, de Man R, et al. Entecavir is superior to lamivudine for the treatment of HBeAg+ve chronic hepatitis B: results of phase III study ETV-022 in nucleoside naive patients (abstract). Hepatology 2004; 40 (Suppl. 1): 193A.
  • 17
    Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Study Group. Gastroenterology 2000; 119: 17280.
  • 18
    Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 152732.
  • 19
    Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 30613.
  • 20
    Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 26370.
  • 21
    Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 75663.
  • 22
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 1019.
  • 23
    Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat 2002; 9: 4248.
  • 24
    Evans AA, Fabre RE, Chen G, Pasternack L, Iloeje UH. Hepatitis B viral load is associated with the development of hepatocellular carcinoma (abstract). Hepatology 2004; 40 (Suppl. 1): 602A.
  • 25
    Chen G, Lin W, Shen FM, Iloeje UH, London WT, Evans AA. Viral load as a predictor of liver disease in chronic hepatitis B infection (abstract). Hepatology 2004; 40 (Suppl. 1): 594A.
  • 26
    Chen CJ, Yang HI, Su J, et al. Viral load is a strong predictor of liver cirrhosis in people chronically infected with hepatitis B virus regardless of HBe antigen status (abstract). J Hepatol 2005; 42 (Suppl. 2): 172.
  • 27
    Iloeje UH, Yang HI, Su J, et al. Serum hepatitis B virus DNA level predicts the incidence of liver cirrhosis in persons chronically infected with HBV (abstract). J Hepatol 2005; 42 (Suppl. 2): 180.
  • 28
    Iloeje UH, Yang HI, Su J, et al. Viral load, not serum ALT is the primary predictor of progression to cirrhosis in persons chronically infected with HBV. Results from a long term prospective study (abstract). J Hepatol 2005; 42 (Suppl. 2): 180.
  • 29
    Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 16874.
  • 30
    Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 152131.
  • 31
    Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002; 36: 140815.
  • 32
    Seo Y, Yoon S, Truong BX, et al. Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. Eur J Gastroenterol Hepatol 2005; 17: 7537.
  • 33
    Gauthier J, Bourne EJ, Lutz MW, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 1999; 180: 175762.
  • 34
    Di Marco V, Di Stefano R, Ferraro D, et al. HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy. Antivir Ther 2005; 10: 4319.
  • 35
    Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 130919.
  • 36
    Perrillo RP, Regenstein FG, Peters MG, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 1988; 109: 95100.
  • 37
    Lok AS, Novick DM, Karayiannis P, Dunk AA, Sherlock S, Thomas HC. A randomized study of the effects of adenine arabinoside 5′-monophosphate (short or long courses) and lymphoblastoid interferon on hepatitis B virus replication. Hepatology 1985; 5: 11328.
  • 38
    Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298302.
  • 39
    Scully LJ, Shein R, Karayiannis P, McDonald JA, Thomas HC. Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. J Hepatol 1987; 5: 518.
  • 40
    Saracco G, Mazzella G, Rosina F, et al. A controlled trial of human lymphoblastoid interferon in chronic hepatitis B in Italy. Hepatology 1989; 10: 33641.
  • 41
    Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996; 15: 22331.
  • 42
    Lopez-Alcorocho JM, Bartolome J, Cotonat T, Carreno V. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral Hepat 1997; 4 (Suppl. 1): 2732.
  • 43
    Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 1239.
  • 44
    Lau G, Piratvisuth T, Luo KX, et al. Peginterferon alpha 2a (40 KD) (Pegasys) monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HbeAg-positive chronic hepatitis B: results from a large multinational study (abstract). Hepatology 2004; 40 (Suppl. 1): 171A.
  • 45
    Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 120617.
  • 46
    Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 7613.
  • 47
    Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994; 21: 64655.
  • 48
    Perrillo RP, Lai CL, Liaw YF, et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002; 36: 18694.
  • 49
    Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298305.
  • 50
    Marcellin P, Lau GKK, Bonino F, et al. Sustained response to peginterferon alpha 2a (40 kDa) (Pegasys) in HbeAg-negative chronic hepatitis B. 1 year follow-up data from a large randomized multinational study (abstract). J Hepatol 2005; 42 (Suppl. 2): 185.
  • 51
    Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 88996.
  • 52
    Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 3006.
  • 53
    Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32 (4 Pt 1): 84751.
  • 54
    Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 2004; 11: 4328.
  • 55
    Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 68796.
  • 56
    Chen CH, Lee CM, Lu SN, et al. Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 2004; 41: 45461.
  • 57
    Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine-resistant mutants. J Virol 2004; 78: 852435.
  • 58
    Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37: 2735.
  • 59
    Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004; 9: 25762.
  • 60
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 80816.
  • 61
    Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B (abstract). J Hepatol 2005; 42 (Suppl. 2): 17.
  • 62
    Marcellin P, Chang T, Lim S, et al. Increasing serologic virologic and biochemical response over time to adefovir dipivoxil 10 mg in HBeAg+ chronic hepatitis B (abstract). J Hepatol 2005; 42 (Suppl. 2): 31.
  • 63
    van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 14215.
  • 64
    Soriano V, Puoti M, Bonacini M, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 22140.
  • 65
    Dienstag JL, Wei LJ, Xu D, Cross A, Kreter B, Wilber R. Entecavir is superior to lamivudine and adefovir in trials of HBeAg-positive and negative hepatitis B infection: a cross-study analysis with published reports. J Hepatol 2005; 42 (Suppl. 2): 174.
  • 66
    Shaw T, Locarnini S. Entecavir for the treatment of chronic hepatitis B. Expert Rev Anti Infect Ther 2004; 2: 85371.
  • 67
    Shouval D, Lai CL, Cheinquer H, et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBEAG-ve chronic hepatitis B: results of phase III trial ETV 027. Hepatology 2004; 40 (Suppl. 1): 73.
  • 68
    Natsuizaka M, Hige S, Ono Y, et al. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region. J Viral Hepat 2005; 12: 1549.
  • 69
    Andreone P, Gramenzi A, Cursaro C, et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 2004; 11: 43942.
  • 70
    Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004; 19: 3239.
  • 71
    Peters MG, Hann HwH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91101.
  • 72
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 8190.
  • 73
    Hadziyannis S, Tassopoulos N, Chang TT, et al. Long term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg negative chronic hepatitis B: results after 5 years of therapy. Hepatology 2005; 43 (Suppl. 1): 755.
  • 74
    Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory HBeAg(+) hepatitis B: Results of phase II study ETV 026. Hepatology 2004; 40 (Suppl. 2): 664.
  • 75
    Levine S, Hernandez D, Yamanaka G, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 252532.
  • 76
    Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498507.
  • 77
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004; 2: 87106.